Price
No data yet.
Social Signal Score
Analyst Ratings
3 analystsRevenue
$51.0KAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Brent T. Lucas
- Sector
- Healthcare
- Industry
- Medical - Devices
- Employees
- 43
- Beta
- 1.90
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- -20.13
Financials
Revenue
$51.0K-49.5%Net Income
$-5.98MEBITDA
$-5.16MFree Cash Flow
$-5.46MEPS (diluted)
$-0.07Shares Outstanding (diluted)
104.04M+72.3%Operating Expenses
$5.34MCash & Debt
$19.68MReturn of Capital
$0.00Revenue by Segment (annual)
$874.0KQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $241.0K | $-23.76M | $-1.23 |
| 2024 | $225.0K | $-20.80M | $-1.49 |
| 2023 | $316.0K | $-29.92M | $-2.54 |
| 2022 | $237.0K | $-15.92M | $-1.57 |
| 2021 | $310.0K | $-8.68M | $-1.05 |
| 2020 | $0.00 | $-701.00 | $0.00 |
Valuation
COCHhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
30-76.47%Social Signal Score
Mentions (3)
- Newsnewsfilecorp.com·8h ago·Negative
…y Early Q2 2027 and Submit Final Clinical PMA Module by End of Q2 2027 White Bear Lake, Minnesota--(Newsfile Corp. - October 20, 2026) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health and neuroprosthetics company pioneering fully implanted hearing solutions, today announced that it has surpassed the six-month follow-up visit milestone for the Company's pivotal clinical trial evaluating the investigational fully implanted Acclaim® cochlear implant. This mi…
View source ↗ - Newszacks.com·71d ago·Negative
Envoy Medical, Inc. (COCH) Reports Q2 Loss, Misses Revenue Estimates Envoy Medical, Inc. (COCH) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to a loss of $0.32 per share a year ago.
View source ↗ - Newsnewsfilecorp.com·71d ago·Negative
Envoy Medical Reports Second Quarter 2026 Results and Achieves Key Regulatory and Clinical Milestones Submitted First Module of Modular PMA Application to FDA Subsequent to Quarter End, the Company Reported Positive 12-Month Stage 1 Data Showing Continued Improvement in Speech Perception White Bear Lake, Minnesota--(Newsfile Corp. - August 10, 2026) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, toda
View source ↗
Earnings
Mon, Nov 9(in 3 weeks)
Consensus estimate $-0.07 per share
Typical surprise -8.3% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Aug 10$-0.07 vs $-0.08beat
- Mon, May 11$-0.11 vs $-0.14beat
- Mon, Mar 23$-0.26 vs $-0.24miss
- Mon, Nov 10$-0.35 vs $-0.27miss
- Thu, Jul 31$-0.32 vs $-0.29miss
- Thu, May 1$-0.29 vs $-0.35beat
Estimates and results for COCH via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by COCH officers and directors.
- Bought
- $35.9m
- Sold
- —
33 trades
0 trades
- Patel Mona Chetanbought
- Patel Mona Chetanbought
- Patel Mona Chetanbought
- Potashnick Robertbought
- Potashnick Robertbought
- Potashnick Robertbought
- Kantor Susanbought
- Kantor Susanbought
67 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in COCH.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.